Agilent Technologies and SomaLogic Enter Agreement to Expand Access to Cutting-Edge Proteomic Technology

  Agilent Technologies and SomaLogic Enter Agreement to Expand Access to
  Cutting-Edge Proteomic Technology

    Microarray-based SOMAscan Assay to Be Installed at Select Academic and
                          Contract Research Centers

Business Wire

SANTA CLARA, Calif. & BOULDER, Colo. -- August 12, 2013

Agilent Technologies Inc. (NYSE: A) and SomaLogic Inc. (a privately held
biotechnology company) announced today that they have entered into an
agreement to expand access to SomaLogic’s unbiased protein biomarker discovery
platform.

The companies will initially place SomaLogic’s SOMAscan proteomic assay, which
employs custom Agilent microarrays in its workflow, in select academic and
contract research centers. Although the SOMAscan assay is already available to
researchers directly from SomaLogic as a service, this planned roll-out is
aimed at meeting the rapidly growing demand for access to SomaLogic’s highly
multiplexed, cost-effective proteomic analyses.

“This agreement will greatly enhance our current microarray offerings by
expanding them into the rapidly growing proteomics market,” said Jacob
Thaysen, vice president and general manager of Agilent’s Genomics Solutions
Division. “SomaLogic’s cutting-edge proteomic technology makes them an ideal
partner for us to increase our presence in this growing market.”

“Agilent’s custom microarrays have been a critical element in our development
of the SOMAscan assay over the past several years,” said Larry Gold, Ph.D.,
chairman and CEO of SomaLogic. “We are delighted that our partnership is
expanding to make the technology even more accessible to researchers
everywhere.”

Terms of the agreement were not disclosed.

About SomaLogic

SomaLogic, Inc., is a privately held biomarker discovery and clinical
diagnostics company based in Boulder, Colo. The company's mission is to use
its proprietary proteomic technology to develop a wide range of enhanced
protein-analysis tools and reagents for the life sciences community, to
facilitate biomarker discovery and validation for diagnostic and therapeutic
applications, and to develop and commercialize clinical diagnostic products
that will improve the delivery of health care by offering timely and accurate
diagnostic information to physicians and their patients. Further information
about SomaLogic can be found at www.somalogic.com.

About SOMAscan/SOMAmers

The SOMAscan proteomic assay utilizes SomaLogic’s proprietary Slow Off-rate
Modified Aptamer (SOMAmer) affinity reagents to cost-effectively detect and
measure 1129 protein analytes across a wide dynamic range in as little as 50
µl of biological sample, with a throughput of nearly a thousand samples per
week, producing millions of useful data points in a short time. Further
information about the applications of this breakthrough proteomic technology
can be found at www.somalogic.com/technology.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics, and communications. The company’s 20,500 employees serve
customers in more than 100 countries. Agilent had revenues of $6.9 billion in
fiscal 2012. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship, and executive news
is available on the Agilent news site at www.agilent.com/go/news.

Contact:

Agilent Technologies Inc.
Eric Endicott, +1 408-553-2005
eric_endicott@agilent.com
or
SomaLogic, Inc.
Fintan R. Steele, Ph.D., +1 720-214-3080
fsteele@somalogic.com
 
Press spacebar to pause and continue. Press esc to stop.